Home

Blog

Beyond Weight Loss: GLP-1 Breakthroughs for Addiction Recovery

Beyond Weight Loss: GLP-1 Breakthroughs for Addiction Recovery

GLP-1s don’t just curb appetite. They may also turn down the brain’s reward signals that drive craving, especially in alcohol use disorder, with early signals for other addictions. Not FDA-approved for this use and not a silver bullet, but the science is moving fast. This guide explains the evidence, the risks, and how GLP-1s could complement real-world recovery.

Uncategorized
19 min read

October 29, 2025

Your Guide to Understanding the Breakthrough Science Behind GLP-1s and Substance Use Disorders

If you’ve been following the news about GLP-1 medications like Ozempic, Wegovy, or Mounjaro, you probably know them as powerful weight loss drugs. But what if we told you that these same medications might hold the key to treating some of our most challenging public health crises—alcohol addiction, drug abuse, and even behavioral addictions like gambling?

This might sound surprising, but groundbreaking research from institutions like Stanford Medicine, the National Institutes of Health, and Brown University is revealing that GLP-1 medications may represent what some experts are calling a “Prozac moment” for addiction treatment—a breakthrough that could transform how we approach substance use disorders.

This comprehensive guide explores the exciting science behind GLP-1s and addiction, what the research shows, how these medications work in the brain, and what this means for the millions of people struggling with addictive behaviors.

Understanding the Addiction Crisis

Before diving into the breakthrough potential of GLP-1s, it’s important to understand the scope of the problem we’re facing.

The Numbers Are Staggering

According to research summarized by the Endocrine Society, substance use disorders represent a major public health challenge, yet less than a quarter of people received treatment in 2023. The barriers are numerous: stigma, limited access to care, high costs, and—perhaps most critically—a shortage of effective medications.

Alcohol is a leading preventable cause of death in the United States, contributing to roughly 178,000 deaths per year, and about 1 in 10 adults meet criteria for alcohol use disorder. Alcohol-associated deaths have significantly increased since the COVID-19 pandemic.

Current Treatments Fall Short

The FDA has approved only three medications for alcohol use disorder (AUD for short): naltrexone, acamprosate, and disulfiram. While these can help some patients, their effectiveness is limited, and many people don’t respond to them at all. As Dr. Joseph Schacht, who’s leading NIH-funded research on GLP-1s and addiction at the University of Colorado, states: “I’ve been working in this area for 15 years, and this is the most exciting drug we’ve seen in that time.”

For other substance use disorders—cocaine, opioids, nicotine—the medication options are equally sparse or missing entirely. This treatment gap has left millions of people struggling without adequate pharmacological support for their recovery.

What Are GLP-1 Medications and How Do They Work?

The Basics

Glucagon-like peptide-1 (GLP-1) receptor agonists are medications that mimic a natural hormone your small intestine releases after you eat. According to Stanford Medicine’s psychiatry research, these drugs slow the movement of food through your gut and boost insulin production, increasing feelings of fullness and suppressing appetite.

Common GLP-1 receptor agonists include:

Semaglutide (Ozempic, Wegovy, Rybelsus)
Tirzepatide (Mounjaro, Zepbound)
Liraglutide (Saxenda; generics available as of 2025; note that Victoza brand was discontinued)
Dulaglutide (Trulicity)

Exenatide (Byetta, Bydureon) was previously used but is discontinued in the U.S.

These medications were originally FDA-approved for treating type 2 diabetes and obesity, and they’ve been remarkably successful in those roles.

How GLP-1s Interact with the Brain’s Reward Circuitry

Here’s where things get fascinating. GLP-1s don’t just make people feel full by delaying stomach emptying. Research published in Endocrinology reveals that they also target the brain’s reward pathway—specifically, influencing the release of dopamine in areas linked to motivation, pleasure, and reward.

Dopamine is the brain’s “feel-good” neurotransmitter, and it plays a central role in addiction. When you consume drugs, alcohol, or engage in pleasurable activities, dopamine firing temporarily increases above baseline in the reward pathway. This creates the “high” that reinforces addictive behaviors.

GLP-1 receptors are widely distributed throughout the brain, including in critical addiction-related regions: the ventral tegmental area (VTA), nucleus accumbens (NAc), prefrontal cortex (PFC), and other areas central to reward processing. By activating these receptors, GLP-1 medications can blunt dopamine release and reduce reward signaling—making addictive substances less appealing.

The Evidence: What Research Shows About GLP-1s and Addiction

Alcohol Use Disorder: The Most Promising Application

The strongest evidence for GLP-1s in addiction treatment comes from alcohol research. Multiple studies have demonstrated remarkable effects:

Preclinical Studies Show Consistent Benefits

According to a comprehensive review in Endocrinology, preclinical studies have demonstrated that GLP-1 receptor agonists:

Decrease alcohol intake
Reduce the motivation to consume alcohol
Reduce relapse-like drinking in animal models
Lower alcohol-induced reward

These effects have been observed across various animal models, from rodents to non-human primates, suggesting the mechanisms are robust and translatable to humans.

Early Human Studies Show Promise; Larger Trials Running Now

A small Phase 2 trial published in JAMA Psychiatry found that semaglutide reduced drinks per drinking day and craving scores compared to placebo, with other outcomes mixed; larger, longer trials are underway. While small in scale, the study provides crucial proof-of-concept evidence that what works in animals also works in humans.

Research conducted at the University of Colorado is testing whether oral semaglutide can curb alcohol cravings. The study uses brain imaging to examine whether the medication reduces activation of brain areas associated with reward when participants are shown pictures of alcohol. Early indications suggest that GLP-1s may work through the same craving-reduction pathways as approved addiction medications—but potentially more effectively.

The Real-World Evidence Is Compelling

Perhaps most exciting are reports from clinical practice. According to Stanford Medicine, patients taking GLP-1s for weight loss or diabetes have spontaneously reported decreased cravings for alcohol—even when they didn’t have problematic drinking patterns before. These unsolicited reports have sparked intense scientific interest in formally studying these effects.

Psychology Today highlighted a case where a patient who struggled with both obesity and alcohol use disorder started taking a GLP-1 medication. Not only did they lose weight, but they also experienced a dramatic reduction in their urge to drink—describing alcohol as suddenly “not appealing” in a way they’d never experienced with other treatments. (Note: This is a journalistic anecdote, not a controlled study.)

Other Substance Use Disorders

While alcohol research is most advanced, emerging evidence suggests GLP-1s may help with other addictions too:

Opioid Use Disorder

Research published in the British Journal of Pharmacology and reviewed by the National Center for Biotechnology Information indicates that GLP-1 receptor agonists can:

Reduce opioid-seeking behavior in animal models
Decrease opioid-induced reward
Potentially help prevent relapse

Given the severity of the opioid crisis, these findings are particularly important. Current medications for opioid use disorder (methadone, buprenorphine, naltrexone) work well for many patients, but not everyone responds, and combination approaches may offer better outcomes.

Nicotine and Smoking

According to research from Brown University’s School of Public Health, GLP-1 medications show promise in reducing nicotine cravings and smoking behavior. Studies in animals demonstrate that GLP-1 receptor agonists:

Reduce nicotine self-administration
Decrease nicotine-seeking behavior
Prevent nicotine-induced dopamine increases

Cocaine and Psychostimulants

Research reviewed in the Journal of the Endocrine Society shows that GLP-1 agonists can reduce cocaine-seeking behavior and cocaine-induced reward in preclinical models. This is particularly exciting because we currently have no FDA-approved medications for cocaine use disorder.

Cannabis Use Disorder

Evidence for cannabis is preliminary. Some observational data suggest associations, but definitive preclinical self-administration or randomized clinical data for GLP-1s and cannabis use disorder are limited; further research is needed.

Behavioral Addictions

The potential benefits of GLP-1s may extend beyond substance use disorders to behavioral addictions like gambling disorder. Stanford Medicine reports that patients have described reduced urges to gamble while taking these medications, suggesting the effects on reward pathways may be broad enough to address process addictions as well.

How Do GLP-1s Work in the Addiction Brain?

Understanding the mechanisms behind GLP-1s’ effects on addiction helps us appreciate why these medications might work and what makes them different from existing treatments.

The Dopamine Connection

As explained in research from Stanford Medicine and detailed in PMC neuroscience reviews, GLP-1 receptor agonists directly affect the brain’s dopamine reward system. Specifically, they:

Reduce Dopamine Firing: GLP-1s decrease dopamine neuron activity in the ventral tegmental area (VTA), the brain’s primary dopamine production center.
Blunt Reward Response: By reducing dopamine release in the nucleus accumbens (the brain’s reward processing hub), GLP-1s make addictive substances less rewarding.
Normalize Reward Sensitivity: Rather than creating a dopamine deficit, GLP-1s appear to restore more normal reward processing—making unhealthy rewards less appealing while maintaining the ability to experience pleasure from healthy activities.

Beyond Dopamine: Multiple Pathways

Research published in the British Journal of Pharmacology reveals that GLP-1s affect addiction through several complementary mechanisms:

Prefrontal Cortex Enhancement: GLP-1 receptors in the prefrontal cortex—the brain’s executive control center—may enhance cognitive control and decision-making abilities. This could help people resist impulses to use substances even when cravings arise.

Amygdala Modulation: The amygdala processes emotional responses and stress-related cues that can trigger addictive behaviors. GLP-1s may reduce the amygdala’s stress and anxiety responses that often precipitate substance use.

Gut-Brain Axis: As detailed in Endocrinology, GLP-1s work through the gut-brain axis—the bidirectional communication system between your digestive system and brain. This connection influences not just hunger and fullness but also mood, motivation, and reward processing.

Nausea and Aversion: Some researchers theorize that GLP-1s may also create mild aversive effects (like slight nausea) when combined with alcohol or drugs, similar to how disulfiram works for alcohol use disorder. However, Brown University researchers note that many patients report reduced cravings without experiencing nausea, suggesting aversion isn’t the only mechanism.

The “Quieting the Noise” Effect

Dr. Anna Lembke at Stanford Medicine describes how patients on GLP-1s for addiction often report that the “noise” in their head about using substances simply quiets down. The constant mental preoccupation with alcohol or drugs—what clinicians call “craving”—diminishes significantly.

This subjective experience aligns with the neurobiological findings: by normalizing dopamine signaling and reducing reward hypersensitivity, GLP-1s may literally quiet the neurological “noise” that drives compulsive use.

Clinical Experience: What Doctors Are Seeing

While large-scale clinical trials are still underway, addiction specialists and psychiatrists are cautiously beginning to prescribe GLP-1 medications off-label for addiction treatment. Here’s what they’re reporting:

Promising Patterns Emerging

According to research from the University of Colorado and insights from Brown University, clinicians are observing:

Rapid Onset: Many patients report decreased cravings within the first few weeks of treatment—much faster than traditional addiction medications.

Sustained Effects: The craving reduction appears to persist as long as patients continue taking the medication, rather than diminishing over time due to tolerance.

Improved Treatment Engagement: Patients with reduced cravings often find it easier to engage in therapy, attend support groups, and implement behavioral changes—creating a positive cycle of recovery.

Multiple Addiction Impact: Some patients report reductions in multiple addictive behaviors simultaneously; controlled evidence is strongest for alcohol so far. For example, someone might experience decreased urges to drink, smoke, and overeat.

Challenges and Considerations

Clinical experience also reveals important limitations and considerations:

Individual Variation: Not everyone responds to GLP-1s for addiction. Just as with any medication, individual differences in brain chemistry, genetics, and life circumstances mean some people benefit dramatically while others see little effect.

Side Effect Burden: GLP-1s commonly cause nausea, vomiting, diarrhea, and other gastrointestinal symptoms, especially when starting treatment. For some patients, these side effects are intolerable, leading to discontinuation.

Cost Barriers: Without FDA approval for addiction treatment, insurance rarely covers GLP-1s for this purpose. Out-of-pocket costs can range from $900 to $1,300 per month for brand-name medications—a prohibitive expense for many people struggling with addiction.

Long-Term Questions: We don’t yet know what happens when someone stops taking GLP-1s after using them for addiction treatment. Do cravings return? At what intensity? How long does protective effect last after discontinuation? These questions need answers.

Who Might Benefit from GLP-1s for Addiction?

Based on current evidence, certain groups may be particularly good candidates for GLP-1 treatment:

Primary Candidates

Alcohol Use Disorder Patients: Given the strongest evidence base, people with problematic alcohol use may be the best candidates, especially those who:

Haven’t responded to traditional medications (naltrexone, acamprosate, disulfiram)
Experience strong cravings that undermine recovery efforts
Want to reduce drinking rather than achieve complete abstinence (harm reduction approach)
Have comorbid obesity or type 2 diabetes (where GLP-1s have FDA approval)

Dual Diagnosis Patients: People with both substance use disorders and obesity/diabetes may benefit from GLP-1s’ effects on multiple conditions simultaneously. According to Psychology Today, this dual benefit can be particularly powerful.

Treatment-Resistant Cases: Individuals who haven’t found success with other approaches may be willing to try GLP-1s despite the off-label status and cost.

Important Exclusions

GLP-1s aren’t appropriate for everyone:

Medical Contraindications: Personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, severe pancreatitis, or severe gastroparesis.

Pregnancy and Breastfeeding: GLP-1s are not recommended during pregnancy or breastfeeding.

Severe Mental Health Instability: The gut side effects and dietary changes required may be too challenging for someone in acute crisis.

History of Eating Disorders: The appetite suppression effects could be problematic for people with anorexia or bulimia.

The Future: Where Is This Research Headed?

The next few years will be critical in determining whether GLP-1 medications become standard addiction treatments. Here’s what’s on the horizon:

Ongoing Clinical Trials

Multiple NIH-funded studies are currently underway, including:

Large-scale trials testing semaglutide for alcohol use disorder
Studies examining tirzepatide (trials are planned or underway; whether its dual GLP-1 and GIP receptor action confers added benefit in addiction remains to be shown) for various addictions
Trials specifically focused on opioid use disorder, cocaine use disorder, and nicotine dependence (known as substance abuse disorders or SUD)
Research on optimal dosing strategies for addiction vs. weight loss/diabetes indications

Key Questions Being Investigated

According to Brown University researchers, several critical questions need answers:

Optimal Dosing: What doses work best for addiction? Are they the same as those used for weight loss and diabetes, or do addiction-specific protocols need development?

Duration of Treatment: How long should patients take GLP-1s for addiction? Are there phases where medication is most helpful (early recovery, relapse prevention, etc.)?

Combination Approaches: How do GLP-1s work when combined with traditional addiction medications like naltrexone, buprenorphine, or acamprosate? Could combination therapy be more effective than either medication alone?

Predictive Biomarkers: Can we identify in advance who will respond to GLP-1s for addiction? Brain imaging, genetic testing, or other biomarkers might help personalize treatment.

Long-Term Outcomes: What happens to recovery rates, relapse rates, and overall quality of life when GLP-1s are added to comprehensive addiction treatment programs?

Regulatory Pathway

Stanford Medicine researchers note that if efficacy and safety are confirmed in ongoing trials, pharmaceutical companies could seek FDA approval for addiction-specific indications in the coming years. This process typically takes several years, but success would:

Enable insurance coverage for addiction treatment
Provide clearer prescribing guidelines
Legitimize GLP-1s as addiction medications in the medical community
Potentially make treatment more accessible to people who need it

The “Prozac Moment” Analogy

Researchers and clinicians have started calling this potential breakthrough a “Prozac moment”—referring to how fluoxetine (Prozac) revolutionized depression treatment in the 1980s and 90s. Before Prozac, depression medications existed but were poorly tolerated and underutilized. Prozac’s tolerability and effectiveness brought depression treatment into the mainstream, reduced stigma, and changed how we think about mental health treatment.

Could GLP-1s do the same for addiction? The parallel is compelling: a medication originally developed for another purpose (diabetes/weight loss) turns out to have profound effects on a major psychiatric condition. If the research pans out, GLP-1s could similarly transform addiction treatment.

Practical Guidance: Should You Consider GLP-1s for Addiction?

If you or someone you love is struggling with addiction, you might be wondering whether to pursue GLP-1 treatment. Here are some practical considerations:

Talk to Your Healthcare Provider

The first step is always consultation with qualified professionals:

Addiction Specialists: Addiction medicine physicians or addiction psychiatrists are best positioned to evaluate whether GLP-1s might help your specific situation.

Primary Care Providers: If you have obesity or type 2 diabetes in addition to addiction concerns, your primary care provider might prescribe GLP-1s for the FDA-approved indication while monitoring effects on substance use.

Prescribing Reality: Many providers are still learning about GLP-1s for addiction. You may need to share research articles (like this one) to inform the discussion. Some providers are willing to prescribe off-label; others are more conservative and prefer waiting for FDA approval.

Cost and Access Considerations

Insurance Coverage: Most insurance plans won’t cover GLP-1s for addiction treatment since it’s off-label. However, if you also have diabetes or obesity, you may get coverage for those FDA-approved indications.

Patient Assistance Programs: Pharmaceutical manufacturers offer patient assistance programs that may reduce costs for eligible individuals. Check manufacturers’ websites for details.

Compounded Options: Some telehealth companies and compounding pharmacies offer lower-cost GLP-1 formulations ($200-$400/month). Quality and efficacy may vary, so research carefully.

Clinical Trials: Participating in research studies often provides free medication and close medical monitoring. Check ClinicalTrials.gov for opportunities.

Comprehensive Treatment Approach

GLP-1s shouldn’t be viewed as a magic bullet or standalone treatment. Stanford Medicine emphasizes that medication is most effective when combined with:

Evidence-Based Therapy: Cognitive-behavioral therapy (CBT), motivational interviewing, contingency management, and other proven counseling approaches.

Support Networks: Mutual aid groups like AA, SMART Recovery, or other peer support communities.

Lifestyle Changes: Exercise, nutrition, sleep hygiene, stress management, and social connection all support recovery.

Addressing Co-Occurring Conditions: Depression, anxiety, PTSD, and other mental health conditions often co-occur with addiction and need treatment.

Medication-Assisted Treatment (MAT): For opioid use disorder specifically, proven medications like buprenorphine and methadone should remain first-line treatments, with GLP-1s potentially added as adjuncts.

Monitoring and Safety

If you start GLP-1 treatment for addiction:

Regular Follow-Up: Work closely with your prescriber to monitor both beneficial effects (reduced cravings, decreased use) and side effects.

Honest Communication: Report any concerning symptoms, especially severe nausea/vomiting, abdominal pain, changes in mood, or suicidal thoughts.

Continued Recovery Work: Don’t stop other treatment approaches just because you start GLP-1s. Maintain therapy, support groups, and healthy habits.

Track Your Response: Keep a journal noting cravings, substance use, side effects, and overall wellbeing. This data helps you and your provider assess whether the medication is working.

Frequently Asked Questions

FAQ 1: Will insurance cover GLP-1 medications for addiction treatment?

Currently, most insurance plans won’t cover GLP-1s specifically for addiction since the FDA hasn’t approved them for this indication. However, if you also have type 2 diabetes or obesity (with BMI ≥30 or ≥27 with comorbidities), you may be able to get coverage under those approved uses. Some people find that treating obesity or diabetes with GLP-1s has the additional benefit of reducing addiction-related cravings.

The coverage landscape could change if ongoing clinical trials lead to FDA approval for addiction indications. Until then, expect to either:

Pay out of pocket (often $900-$1,300/month for brand medications)
Use manufacturer patient assistance programs
Explore lower-cost compounded options through telehealth services
Participate in clinical research trials that provide medication for free

FAQ 2: How long do I need to take GLP-1 medications for addiction?

We don’t yet have definitive answers about optimal treatment duration for addiction. Current addiction medications vary widely:

Methadone and buprenorphine for opioid use disorder are often taken for years or indefinitely
Naltrexone might be used for several months to years
Disulfiram is typically used as long as needed to maintain sobriety

Based on how GLP-1s work (by reducing reward signaling and cravings), most experts predict they’ll need to be taken continuously to maintain benefits—similar to how antidepressants work for depression. When people stop taking GLP-1s, their brain chemistry gradually returns to baseline, which could allow cravings to return.

Research is underway to determine:

Whether there’s a minimum effective duration
If benefits persist after discontinuation
Whether intermittent use or maintenance dosing strategies might work
How long protection against relapse lasts after stopping

For now, discuss treatment duration with your provider based on your individual response, recovery progress, side effects, and cost considerations.

FAQ 3: Can I take GLP-1s with other addiction medications like naltrexone or buprenorphine?

This is an important question with limited data. Early clinical experience suggests GLP-1s can be safely combined with other addiction medications, but we lack large-scale studies specifically examining these combinations.

Theoretical Compatibility: GLP-1s and traditional addiction medications work through different mechanisms:

Naltrexone blocks opioid receptors
Buprenorphine partially activates opioid receptors
Acamprosate modulates glutamate
GLP-1s affect dopamine and reward pathways

Because they target different brain systems, combining them shouldn’t create direct pharmacological conflicts. In fact, targeting multiple pathways simultaneously might be more effective than single-medication approaches.

Practical Considerations: If you’re already taking an addiction medication that’s working, adding a GLP-1 might provide additional benefit. If your current medication isn’t working well, a GLP-1 could be tried as a replacement or addition.

Medical Supervision Required: Any medication combination should be monitored by your healthcare provider, who can watch for unexpected interactions, side effects, or response patterns.

FAQ 4: What are the most common side effects of GLP-1 medications?

GLP-1 medications can cause significant side effects, particularly gastrointestinal symptoms:

Very Common (>10% of users):

Nausea (especially in first few weeks)
Vomiting
Diarrhea
Abdominal pain or discomfort
Constipation
Decreased appetite

Common (1-10% of users):

Fatigue
Headache
Dizziness
Indigestion
Acid reflux or heartburn
Injection site reactions (redness, itching)

Less Common but Serious:

Pancreatitis (severe abdominal pain radiating to back)
Gallbladder problems
Kidney problems
Severe allergic reactions
Vision changes (diabetic retinopathy worsening)
Increased heart rate

Rare but Important:

Medullary thyroid cancer (in animal studies; unknown human risk)
Suicidal thoughts or behavior (regulators including FDA and EMA have not found evidence of a causal link between GLP-1s and suicidal thoughts to date, but are continuing to monitor. See FDA 2024 evaluation and EMA 2023 review.)

Most side effects are worst in the first few weeks and improve as your body adjusts. Starting with low doses and titrating up slowly can minimize side effects. If nausea is severe, anti-nausea medications can help. Always report concerning symptoms to your healthcare provider immediately.

FAQ 5: Do GLP-1 medications work for all types of addiction?

Based on current research, GLP-1s show the most promise for alcohol use disorder, with substantial preclinical evidence and growing clinical trial data. However, effects appear to extend to multiple addiction types:

Strong Evidence:

Alcohol use disorder (multiple clinical trials, consistent preclinical findings)

Moderate Evidence:

Opioid use disorder (solid preclinical data, limited clinical evidence)
Nicotine dependence (preclinical evidence, anecdotal clinical reports)
Cocaine use disorder (preclinical studies)

Preliminary Evidence:

Cannabis use disorder (early preclinical data)
Behavioral addictions like gambling (case reports)
Other substance use disorders (theoretical mechanisms)

Individual Variation: Even within well-studied addiction types, not everyone responds to GLP-1s. Factors that might influence response include:

Genetic differences in GLP-1 receptors or dopamine systems
Severity and duration of addiction
Presence of co-occurring mental health conditions
Individual brain chemistry and reward sensitivity
Lifestyle factors and social support

We need more research to understand which specific addiction types benefit most and which patient characteristics predict response.

FAQ 6: Are there any long-term risks of taking GLP-1 medications?

GLP-1 medications have been used for type 2 diabetes since 2005 and obesity since 2014, giving us nearly two decades of safety data for those indications. However, long-term safety specifically for addiction treatment is less clear since this is a newer application.

Known Long-Term Considerations:

Thyroid Cancer Risk: Animal studies showed increased thyroid C-cell tumors, but human epidemiological data hasn’t confirmed elevated cancer risk. People with personal/family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 should not use GLP-1s.

Gallbladder Disease: Rapid weight loss with GLP-1s may increase gallstone risk. Some studies show moderately increased gallbladder problems with long-term use.

Pancreatitis: While rare, pancreatitis risk may be slightly elevated with GLP-1 medications. Anyone with history of pancreatitis should discuss risks carefully with their provider.

Bone Health: Rapid weight loss can affect bone density. Adequate calcium and vitamin D intake, along with weight-bearing exercise, are important during treatment.

Muscle Loss: GLP-1-associated weight loss includes some muscle tissue loss. Protein intake and strength training help preserve muscle mass.

Gastrointestinal Changes: Long-term effects on gut motility and digestive function are still being studied.

Cardiovascular Effects: Interestingly, some GLP-1s show cardiovascular benefits in people with diabetes and obesity. Whether these benefits extend to addiction treatment populations is unknown.

Unknown Long-Term Considerations:

Effects on brain structure and function after years of use
Impact on addiction recovery trajectories over decades
Potential for tolerance or diminishing effectiveness
Consequences of long-term dopamine reward modulation

The best approach is regular monitoring with your healthcare provider, including appropriate lab work and screening for potential complications.

FAQ 7: Will I gain weight or have cravings return if I stop taking GLP-1s?

This is one of the most pressing questions patients ask, and unfortunately, we don’t have complete answers yet, especially for addiction applications.

Weight Regain: For obesity treatment, research clearly shows that most people regain significant weight after stopping GLP-1 medications. Studies indicate average regain of about two-thirds of lost weight within a year of stopping. This occurs because:

GLP-1s suppress appetite, so hunger increases when medication stops
Metabolic rate may have slowed during weight loss
Biological mechanisms favoring weight regain activate

Craving Return: For addiction, we have less data but emerging patterns:

Biological Plausibility: Since GLP-1s work by modulating brain reward pathways, it’s logical that discontinuing them would allow reward sensitivity to return to pre-treatment levels. This could mean cravings gradually increase after stopping.

Clinical Observations: Some patients report craving return within weeks of stopping, while others maintain reduced cravings for months. Individual variation is substantial.

Comparison to Other Medications: With naltrexone for alcohol use disorder, cravings typically return relatively quickly after stopping. With antidepressants, some people maintain benefits for months after discontinuation while others relapse quickly. GLP-1s might follow a similar pattern.

Strategies to Minimize Craving Return:

Don’t stop abruptly without medical guidance
Consider gradual dose tapering
Ensure strong behavioral supports are in place (therapy, support groups, lifestyle changes)
Time discontinuation strategically (not during high-stress periods)
Have relapse prevention plan ready
Consider maintenance dosing or intermittent use if possible
Be prepared that long-term or lifelong treatment might be necessary—similar to how many people need long-term antidepressants or other psychiatric medications

FAQ 8: How do I know if GLP-1s are working for my addiction?

Monitoring your response to GLP-1 treatment involves tracking several indicators:

Craving Reduction: This is often the first and most noticeable change. You might notice:

Thinking about alcohol or drugs less frequently
Less intense urges when triggers appear
Ability to resist urges more easily
The “mental noise” about using substances quiets down

Behavioral Changes: Look for:

Decreased substance use (quantity and/or frequency)
Fewer lapses or relapses
Better ability to engage in sober activities
Improved attendance at therapy or support groups
More consistent follow-through on recovery commitments

Quality of Life Improvements:

Better mood and energy
Improved relationships
Enhanced work or school performance
Better physical health markers
More stable daily routines

Timeline: Most patients who respond to GLP-1s notice craving reduction within 2-4 weeks. Behavioral changes typically follow as reduced cravings make recovery work easier. Full benefits might take 2-3 months to emerge.

Keep a Journal: Track daily:

Craving intensity (0-10 scale)
Number of drinks/uses
Situations where you felt triggered
Side effects experienced
Overall sense of wellbeing

Discuss with Your Provider: Share your tracking data during follow-up appointments. Your provider can help interpret whether the medication is providing meaningful benefit vs. placebo effect vs. insufficient response.

When to Adjust: If you’re not seeing benefits after 6-8 weeks at therapeutic doses, discuss with your provider whether:

Dose adjustment is needed
Switching to a different GLP-1 might help
Combination with other medications should be tried
GLP-1s might not be the right approach for you

FAQ 9: What happens if I stop taking GLP-1 medications? Can I stop cold turkey?

Tapering vs. Abrupt Stopping: No clear guidelines exist yet for how to discontinue GLP-1s when used for addiction. Some providers recommend gradual tapering to allow adjustment, while others note that GLP-1s don’t cause withdrawal syndromes that would necessitate tapering. This area needs more research.

Anecdotal Example: An anecdotal report describes a patient who took liraglutide for alcohol use disorder for 14 months while engaging in intensive therapy and recovery support. When medication was discontinued due to insurance loss, cravings returned mildly after 3-4 weeks but remained manageable using behavioral skills learned in treatment. Six months post-medication, they maintained sobriety with occasional mild cravings handled through support group attendance and coping strategies.

Takeaway: Discontinuation response is highly individual. Don’t stop abruptly without medical guidance. Ideally, discontinue only after establishing strong behavioral support systems. Be prepared for possible craving return and have relapse prevention plan ready. Some people may need long-term or intermittent treatment—this isn’t failure.

FAQ 10: Are compounded GLP-1s as effective for addiction as brand-name medications?

This is a complex question without clear answers, as virtually all research on GLP-1s and addiction has used brand-name, FDA-approved medications (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, etc.), not compounded versions.

What Are Compounded GLP-1s?: Compounding pharmacies create custom formulations of medications, often at lower costs than brand versions. Compounded semaglutide and tirzepatide have become widely available through telehealth companies.

The Uncertainty: Research published in addiction journals examines FDA-approved semaglutide and tirzepatide with known purity, potency, and pharmacokinetic profiles. Compounded versions may have different:

Actual concentration of active ingredient
Stability and degradation rates
Bioavailability (how much enters bloodstream)
Presence of salts vs. base forms of the drug

According to recent FDA guidance, the agency has received hundreds of adverse event reports related to compounded GLP-1s, raising quality concerns. FDA has specifically warned about compounded products labeled as semaglutide “sodium” or “acetate,” which are not the same as the approved active ingredient. However, brand-name medications also have adverse event reports, so this alone doesn’t prove compounded versions are less safe or effective—just that quality may be more variable.

Theoretical Considerations: If compounded GLP-1s are chemically identical to brand versions and properly formulated, they should work similarly for addiction. However, “if” is doing a lot of work in that sentence. Some compounding pharmacies maintain excellent standards; others may not.

Practical Realities: Many patients access compounded GLP-1s for addiction because:

Insurance doesn’t cover brand versions for this use
Out-of-pocket brand costs are prohibitive
Telehealth companies make access convenient
Compounded costs ($200-$400 monthly) are more manageable than brand costs ($900-$1,300)

Anecdotal Example: An anecdotal report describes a patient who used compounded semaglutide from a reputable 503B compounding facility for alcohol use disorder, experiencing similar craving reductions reported in research studies. After insurance coverage changed, they switched to brand Wegovy and noticed no difference in effects. However, this is anecdotal—individual experiences vary widely.

Takeaway: Research specifically on compounded GLP-1s for addiction doesn’t exist. Brand medications have clearer evidence and quality assurance. If using compounded versions, choose reputable 503B-registered facilities, discuss with your provider, and monitor effects carefully. Brand versions are preferable if accessible and affordable.

References

Lembke, A. (2025). Five things to know about GLP-1s and addiction. Stanford Report. Retrieved from https://news.stanford.edu/stories/2025/04/glp1-ozempic-addiction-treatment-research
Leggio, L., et al. (2025). GLP-1s show promise in treating alcohol and drug addiction [Press release]. Endocrine Society News. Retrieved from https://www.endocrine.org/news-and-advocacy/news-room/2025/glp1s-show-promise-in-treating-alcohol-and-drug-addiction
Jerlhag, E. (2025). GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder. Endocrinology, 166(4), bqaf028. doi:10.1210/endocr/bqaf028. Retrieved from https://academic.oup.com/endo/article/166/4/bqaf028/8029141
Fidler, B., & Wu, G. (2025). New study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings. BioPharma Dive. Retrieved from https://www.biopharmadive.com/news/ozempic-glp-1-alcohol-use-disorder-jama-study/739871/
Hendershot, C. S., et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 82(4), 395-405. doi:10.1001/jamapsychiatry.2024.4789. Retrieved from https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811
Schacht, J. (2025). CU Researcher Studying Effects of GLP-1 Drugs on Alcohol Addiction. CU Anschutz Today. Retrieved from https://news.cuanschutz.edu/medicine/cu-researcher-studying-effects-of-glp-1-drugs-on-alcohol-addiction
Haass-Koffler, C. (2025). A turning point in addiction psychiatry? Brown University School of Public Health. Retrieved from https://sph.brown.edu/news/2025-07-24/brain-science-glp-1s-addiction
Alves, D., et al. (2025). Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights. Med Sci (Basel), 13(3), 136. PMCID: PMC12372146. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12372146/
Thomsen, M., et al. (2021). The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. British Journal of Pharmacology, 178(4). Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8820218/
Glasner, S. (2025). Can GLP-1 Medications Help Treat Alcohol Use Disorder? Psychology Today. Retrieved from https://www.psychologytoday.com/us/blog/harm-reduction-or-abstinence/202504/can-glp-1-medications-help-treat-alcohol-use-disorder
Hendershot, C., et al. (2024). Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review. eClinicalMedicine (The Lancet). Retrieved from https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00499-1/fulltext
U.S. Food and Drug Administration. (2025). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
Advisory Board. (2025). The GLP-1 shortage is over. What’s next for compounders? Advisory Board Daily Briefing. Retrieved from https://www.advisory.com/daily-briefing/2025/02/25/compounded-glp-1
Advisory Board. (2025). Companies find ways around end of GLP-1 shortage. Advisory Board Daily Briefing. Retrieved from https://www.advisory.com/daily-briefing/2025/05/27/glp-1-compounders
Maven Financial Partners. (2025). GLP-1 Shortage Ends: What Medspas Need to Know in 2025. Retrieved from https://www.mavenfp.com/post/what-the-end-of-the-weight-loss-medication-shortage-means-for-medspas
Barrie, R. (2025). The GLP-1 drug shortage is over. What’s next for the compounders? Pharma Technology Focus, Issue 154. Retrieved from https://pharma.nridigital.com/pharma_may25/the-glp-1-drug-shortage-is-over-whats-next-for-the-compounders
Centers for Disease Control and Prevention. (2024). About Alcohol Use. CDC.gov. Retrieved from https://www.cdc.gov/alcohol/about-alcohol-use/index.html
National Institute on Alcohol Abuse and Alcoholism. (2024). Alcohol Facts and Statistics. NIAAA.nih.gov. Retrieved from https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics
National Institute on Alcohol Abuse and Alcoholism. (2024). Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristics. NIAAA.nih.gov. Retrieved from https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics
U.S. Food and Drug Administration. (2024). FDA Drug Safety Communication: FDA continues to evaluate reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonists. FDA.gov. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-continues-evaluate-reports-suicidal-thoughts-or-actions-patients-taking-glp-1-receptor-agonists
European Medicines Agency. (2023). EMA statement on ongoing review of GLP-1 receptor agonists. EMA.europa.eu. Retrieved from https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. GLP-1 medications are not FDA-approved for treating addiction. Always consult qualified healthcare providers before making any decisions about your treatment. The information presented here is based on current research, which is ongoing and evolving. Treatment decisions should be made in consultation with addiction specialists, psychiatrists, and/or primary care providers who understand your complete medical history.

If you or someone you know is struggling with substance use disorder, please contact:

SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7)
988 Suicide & Crisis Lifeline: 988
Crisis Text Line: Text HOME to 741741

At FancyMeds, we’re committed to providing evidence-based information about GLP-1 medications and supporting your health journey. While this emerging research on addiction is exciting, we encourage comprehensive treatment approaches that combine medication (when appropriate), therapy, lifestyle changes, and strong support systems. Your path to wellness deserves expert guidance every step of the way.